Research Article
Clinical Course, Prognosis, and Cause of Death in Primary Sjögren’s Syndrome
Table 3
Frequency of clinical and immunoserological features during the disease course.
| | Clinical and serological features | Frequency (%) | Distribution according to gender () | value | | Female () | Male () |
| | EGMs | | | | | | Polyarthritis () | 48.1 | 218 | 42 | <0.001 | | Raynaud's phenomenon () | 39.9 | 213 | 5 | <0.001 | | Vasculitis () | 25 | 126 | 11 | 0.203 | | Lymphadenopathy () | 9.3 | 46 | 6 | 0.89 | | Myositis () | 6.9 | 35 | 5 | 0.748 | | Lung fibrosis () | 6.2 | 31 | 3 | 0.679 | | Renal manifestation () | 5.5 | 26 | 3 | 0.912 | | Serositis () | 5.3 | 29 | 1 | 0.169 | | Associated disorders | | | | | | Thyroiditis () | 13.9 | 77 | 0 | 0.001 | | Microscopic colitis () | 3.5 | 17 | 3 | 0.436 | | LPD () | 3.3 | 15 | 4 | 0.152 | | APS () | 2.7 | 15 | 0 | 0.168 | | Autoimmune hepatitis () | 1.6 | 10 | 1 | 0.840 | | Sarcoidosis () | 1.5 | 6 | 2 | 0.201 | | ITP () | 1.3 | 7 | 0 | 0.350 | | Serological positivity | | | | | | ANA () | 64.6 | 316 | 37 | 0.623 | | anti-ENA () | 78.9 | 382 | 50 | 0.38 | | anti-SS-A () | 76.9 | 372 | 49 | 0.359 | | anti-SS-B () | 55.2 | 277 | 25 | 0.025 | | anti-DNA () | 13.7 | 72 | 3 | 0.038 | | RF () | 29.8 | 130 | 33 | <0.001 | | anti-CCP () | 7.3 | 34 | 6 | 0.397 | | anti-TG () | 8.8 | 48 | 0 | 0.011 | | anti-TPO () | 18.5 | 101 | 1 | <0.001 | | Hypergammaglobulinemia () | 69.6 | 338 | 43 | 0.719 | | Hypocomplementemia () | 21.8 | 106 | 13 | 0.986 | | Cryoglobulinemia () | 6.2 | 32 | 2 | 0.567 |
|
|
values indicate differences between genders. LPD: lymphoproliferative disorders; APS: antiphospholipid syndrome; ITP: immune thrombocytopenic purpura; ANA: antinuclear antibody, ENA: antibody to extractable nuclear antigen; DNA: anti-DNA antibody; RF: rheumatoid factor; TG: antibodies to thyroglobulin; TPO: antibodies to thyroid peroxidase.
|
